MPM is helping to advance cancer research and care through its innovative approach to investing and its partnerships with the American Association for Cancer Research, the UBS Optimus Foundation and Dana-Farber Cancer Institute


Our Focus

MPM Capital is a world-leading biotechnology investment firm with nearly three decades of experience creating and investing in companies that seek to translate scientific innovations into cures for major diseases. With its world-class team and deep experience in scientific research, clinical development, and company-building, MPM strives to power novel medical breakthroughs that transform patients’ lives. MPM invests across the biotech landscape with early-stage venture capital funds, and with impact and public equities products through its affiliate BioImpact Capital.

Focus Area


Exit Type



  1. 2022
  2. 2021
  3. 2020
  4. 2019
  5. 2018
  6. 2017
  7. 2016
  8. 2015
  9. 2014